Uploaded July 2023 | Updated September 2026, 3 weeks ago

---

Please support our work and enable us to continue to share these talks for free by donating at paypal.me

Group sessions can make psychedelic treatment more accessible: Empirical evidence

At current costs, many people who could benefit from psychedelic therapy will not be able to
afford or access it. Eventual adoption by insurers may increase access, but will depend on
demonstrating cost-effectiveness. One strategy to lower costs is to incorporate group sessions
into the treatment regimen. We compared the costs of group and individual psilocybin therapy
for end of life distress and for MDMA therapy for PTSD using empirical cost data. We present
our methods and results and explore implications for cost savings, access and the effective
supply of trained therapists.

Dr. Marseille is a leading expert on the economics of the emerging psychedelic-
assisted therapies. He is the founding Director of the UC Berkeley Global
Initiative for Psychedelic Science Economics (GIPSE), a network of health
economists and health services researchers dedicated to realizing the potential of
psychedelic therapies for high-priority mental health conditions. Through the
application of policy-relevant economic analyses, GIPSE seeks to enhance the
efficiency of service delivery, and increase access to these promising therapies.